Edwards Lifesciences Corporation
EWBusiness Overview
ticker: EW step: 01 generated: 2026-05-12 source: quick-research
Edwards Lifesciences Corporation (EW) — Business Overview
Business Description
Edwards Lifesciences is a global medical technology leader focused exclusively on structural heart disease and critical care monitoring. Headquartered in Irvine, California, and founded in 1958, Edwards pioneered transcatheter aortic valve replacement (TAVR) — a minimally invasive heart valve procedure — and remains the dominant market leader in this transformative technology. In 2023, Edwards divested its Critical Care segment to Becton Dickinson to sharpen its focus on structural heart technologies, creating a pure-play with ~79% gross margins and a long runway of clinical expansion.
Revenue Model
Edwards earns revenue from selling proprietary single-use medical devices (heart valves, delivery systems, repair tools) to hospitals and cardiac catheterization labs worldwide. The model is not subscription-based — it is procedure-driven, meaning revenue scales with the number of structural heart procedures performed globally. Gross margins exceed 79% due to the proprietary technology, clinical data barriers, and regulatory moats. R&D investment is ~18% of sales, funding next-generation platforms and clinical trials that defend market leadership.
Products & Services
- TAVR (74% of 2025 revenue): Sapien 3, Sapien 3 Ultra RESILIA — transcatheter aortic valve replacement; world's first and market-leading platform; now approved in asymptomatic severe aortic stenosis patients (FDA approved 2025)
- TMTT (9% of 2025 revenue): PASCAL system (mitral/tricuspid repair), EVOQUE (tricuspid replacement), SAPIEN M3 (mitral replacement) — fastest-growing segment, projected +35–45% in 2026
- Surgical Structural Heart (17% of 2025 revenue): Inspiris RESILIA surgical aortic valves, KONECT RESILIA conduit — sold to cardiac surgeons for open heart procedures
- Critical Care: Divested to BD in late 2023
Customer Base & Go-to-Market
Hospitals and interventional cardiology programs in 100+ countries. Sales are made directly to hospital systems, with clinical specialists (field reps) embedded in catheterization labs to support procedures. The installed base of TAVR programs (~700+ in the US alone) provides a sticky, recurring demand for valve replacements as the procedure becomes the standard of care. Payer coverage (Medicare/Medicaid NCD) drives adoption.
Competitive Position
Edwards holds ~65–70% of the US TAVR market (Sapien platform vs. Medtronic's Evolut at ~30–35%). The moat rests on: (1) 10+ years of clinical outcomes data across millions of patients — the most compelling evidence base in the field; (2) an FDA-approved label expanded to asymptomatic patients (2025), creating a structurally larger addressable market; and (3) TMTT franchises (PASCAL, EVOQUE) that extend the relationship with structural heart programs into the growing mitral/tricuspid space. The FTC blocked Edwards' planned JenaValve acquisition in early 2026, forcing reliance on internal R&D for AR (aortic regurgitation) treatment.
Key Facts
- Founded: 1958 (as Edwards Laboratories)
- Headquarters: Irvine, California
- Employees: ~16,000
- Exchange: NYSE
- Sector / Industry: Health Care / Health Care Equipment
- Market Cap: ~$48B (approximate, early 2026)
Financial Snapshot
ticker: EW step: 04 generated: 2026-05-12 source: quick-research
Edwards Lifesciences Corporation (EW) — Financial Snapshot
Income Statement Summary
| Metric | FY2022 | FY2023 | FY2024 | YoY |
|---|---|---|---|---|
| Revenue | ~$5.38B* | $5.01B | $5.44B | +9% |
| Gross Margin | ~81% | ~76.8% | ~79.5% | +270bps |
| Operating Margin | ~26% | ~23% | ~25% | |
| Net Income | ~$1.5B | ~$1.1B | ~$1.3B | |
| EPS (GAAP diluted) | ~$2.40 | $2.02 | $2.34 | +16% |
FY2022 includes Critical Care segment divested to BD in 2023.
Cash Flow & Balance Sheet (FY2023/FY2024)
| Metric | Value |
|---|---|
| Operating Cash Flow | ~$1.2B |
| Free Cash Flow (adj.) | ~$943M (FY2023) |
| Cash & Equivalents | ~$1.9B |
| Total Debt | ~$0.6B |
Note: EW carries minimal debt — a net cash position. Balance sheet is exceptionally clean post-Critical Care divestiture.
Key Ratios (approximate)
- P/E (forward FY2026): ~28–32x | EV/EBITDA: ~22x | FCF Yield: ~2%
- Revenue Growth (FY2024): +9% | Gross Margin: ~79.5%
Growth Profile
Edwards is a focused structural heart pure-play growing mid-to-high single digits in TAVR and 35–45%+ in TMTT. The asymptomatic TAVR approval (FDA 2025) expands the addressable population meaningfully — severe aortic stenosis affects ~500,000 people annually in the US, and treating earlier (before symptoms emerge) could expand procedures by 20–30% over time pending NCD update. TMTT is becoming a second growth engine, targeting the 5M+ patients with mitral/tricuspid valve disease who have no good treatment option today.
Forward Estimates
- FY2026: Revenue growth 8–10% constant currency; TAVR $4.6–4.9B; TMTT $740–780M (+35–45%); adj. EPS guidance $2.80–$2.95
- Long-term: Structural heart disease addressable market estimated >$10B globally; TMTT alone could reach $1B+ by 2027
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $EW.